Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines

Stock News12-15

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. ("Shangyao Zhongxi"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.

Hydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.

The approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153257892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 16:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153257892","market":"hk","top_or_hot":-1,"title":"Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.</p>\n<p>Hydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.</p>\n<p>The approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-15 16:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.</p>\n<p>Hydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.</p>\n<p>The approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0184","symbol_name":"上海国资改革","start_time":0,"source_url":"","article_id":"1153257892","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153257892","pubTimestamp":1765786358,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0184":"上海国资改革","BK0028":"国家队","BK0099":"上海本地重组","BK0097":"医药电商","BK1197":"保健护理产品经销商","BK0020":"浦东新区","BK0183":"MSCI概念","BK0209":"零售","02607":"上海医药","BK0188":"融资融券","BK0175":"白马股","BK0012":"证金概念","BK0196":"行业龙头","BK0187":"一线龙头"},"translate_title":"上海医药（601607.SH）：硫酸羟氯喹片获菲律宾药品注册证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.\nHydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.\nThe approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153257892","isCrawlerRequest":true}